Chrystal Louis serves as Chief Medical Officer at TScan Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Chrystal Louis has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 20, 2026 involved receiving (via award) 420,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 20, 2026 | TCRX | $0 | Award | 420,000 | $N/A | Discretionary |
Chrystal Louis currently holds 420,000 shares of TScan Therapeutics, Inc. (TCRX), valued at approximately $0. This represents their equity stake as Chief Medical Officer.
Based on SEC Form 4 filings, Chrystal Louis has been a net neutral trader of TCRX stock. They have purchased $0 and sold $0 worth of shares.
Chrystal Louis's most recent insider trade was on Jan 20, 2026, when they sold 420,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted